Overview Fundamentals API Earnings EOD API Sample Code Pricing

AbbVie Inc (4AB F) stock market data APIs

€175.34 0(0%) as of October 29, 2024

Price chart is built with Anychart

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc Financial Data Overview

Prev. Close	175.34
Open	175.34
Volume	-
High	175.34
Low	175.34
52 wk Range	120.6905-179.2431
Market Cap	310 806 M
P/E Ratio	63.2996
Shares Outstanding	1 766 M
Revenue	55 000 M
EPS
Dividends (Yield)	0.0325
Beta	0.618

Our easy-to-use no-coding solutions help you get the data effortlessly:

Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

Prices start at $19.99/month

General: {

Code: '4AB',

Type: 'Common Stock',

Name: 'AbbVie Inc',

Exchange: 'F',

CurrencyCode: 'EUR',

CurrencyName: 'Euro',

CurrencySymbol: '€',

CountryName: 'Germany',

CountryISO: 'DE',

OpenFigi: NULL,

ISIN: NULL,

CIK: NULL,

EmployerIdNumber: NULL,

FiscalYearEnd: 'December',

IPODate: NULL,

InternationalDomestic: NULL,

Sector: 'Healthcare',

Industry: 'Drug Manufacturers - General',

CUSIP: NULL,

}

AbbVie Inc Fundamental Data is available in our Financial Data APIs

Net Revenue 55 000 M
EBITDA 26 121 M
Earnings Per Share 2.77
Income Statements
Balance Sheets
Cash flows

Fundamental data package from $59.99 See full price

Get sample
of Fundamental API Data

Get AbbVie Inc Earnings via APIs

Latest Release 2024-10-30
EPS/Forecast NaN

Calendar package from $19.99 See full price

Get sample
earnings calendar API

Get AbbVie Inc End-of-day Data via APIs

End of Day, Intraday and Live APIs
Splits
Dividends

All world package from $19.99 See full price

Get sample
of End-of-Day API Data

Get AbbVie Inc latest news via APIs

AbbVie is buying an Alzheimer's drug for more than $1 billion

2 days ago

AbbVie (ABBV) announced Monday that it is buying Aliada Therapeutics for $1.4 billion. The deal includes Aliada’s lead drug candidate ALIA-1758, an experimental antibody being tested for treating Al...

Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process

1 week ago

MONTREAL, Oct. 21, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Rel...

News API is available at any package from $19.99 See full price

Get sample of News API

Robust, powerful and easy to use

Our advantages

Prices start at
$19.99

Fast+ support 24/7 via web-chat and email

Robust, powerful and reliable data

One click API for all financial data you need

Sample code for your quick start

Ready-to-go solutions

Our easy-to-use no-coding solutions help you get the data directly to MS Excel and Google Sheets. Or download the CSV (TXT) files effortlessly with tools for Windows and Linux.

Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

Best price for all data API

Prices start at $19.99/month

All-In-One

$99.99/per month

100 000+ API requests per day
EOD Data - All World Extended
Splits and Dividends
Fundamental Data
Bonds Data
Options Data
1000+ currency pairs
1000+ cryptocurrency pairs

Do you have any questions?

support@eodhistoricaldata.com